TP53 and lip and oral cavity carcinoma: Therefore, studying the expression levels and activity of BCL2, BAX, and P53 in response to ZnO-PIP NPs treatment provides valuable insights into the underlying mechanisms of their anticancer effects and elucidates potential therapeutic targets for combating oral cancer.